NCT07477457 2026-03-17
A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
Memorial Sloan Kettering Cancer Center
The Institute of Molecular and Translational Medicine, Czech Republic
Olympion Medical Center
Wake Forest University Health Sciences
University of Utah
HonorHealth Research Institute
National Cancer Institute, Slovakia
National Cancer Institute, Slovakia